RayzeBio plans IPO to push radiotherapy 'pipeline-in-a-product' through phase 3

RayzeBio has already persuaded investors to hand over more than $400 million to pursue its targeted radiation approach to treating cancer. Now, with its lead product in phase 3 trials, the biotech is eyeing up an IPO to push its plans forward.